Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Del(14)(q22) in diffuse B-cell lymphocytic lymphoma.

H Tilly¹, C Bastard, E Halkin

¹Centre Henri Becquerel, Rouen, France.

American Journal of Clinical Pathology

|January 1, 1988

Summary

A specific chromosomal abnormality, deletion 14q22, may identify a non-Hodgkin

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Combining Total Metabolic Tumor Volume With Beta-2-Microglobulin Levels Predicts Outcomes in High-Burden Follicular Lymphoma Patients.

Hematological oncology·2024

Same author

Prognostic value of the combination of volume, massiveness and fragmentation parameters measured on baseline FDG pet in high-burden follicular lymphoma.

Scientific reports·2024

Same author

Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Same author

Cell therapy for posttraumatic shoulder osteonecrosis.

Morphologie : bulletin de l'Association des anatomistes·2020

Same author

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

Same author

Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma.

European journal of nuclear medicine and molecular imaging·2018

Area of Science:

Genetics
Hematology
Oncology

Background:

Recurrent chromosomal abnormalities are linked to specific non-Hodgkin's lymphoma (NHL) subtypes.
Understanding these genetic alterations is crucial for lymphoma classification and treatment.

Purpose of the Study:

To investigate the potential association between a specific chromosomal deletion, del(14)(q22), and a distinct subtype of non-Hodgkin's lymphoma (NHL).
To explore the role of del(14)(q22), potentially with trisomy 12, in the pathogenesis of B-cell lymphomas.

Main Methods:

Karyotype analysis was performed on 62 patients diagnosed with NHL.
Immunoglobulin surface and monoclonal antibody phenotyping were used to determine lymphoma cell origin.
Detailed analysis of chromosomal abnormalities, specifically del(14)(q22) and trisomy 12, was conducted.

Related Experiment Videos

Main Results:

Three out of 62 NHL patients exhibited del(14)(q22).
These three cases presented with diffuse lymphoma, generalized lymphadenopathy, and bone marrow involvement.
All three lymphomas were confirmed to be of B-cell origin.
Trisomy 12 was observed in conjunction with del(14)(q22) in these patients.

Conclusions:

The chromosomal abnormality del(14)(q22), possibly with trisomy 12, may serve as a marker for a specific subtype of non-Hodgkin's lymphoma.
Chromosome 14, band 22, might play a role in the development and progression of B-cell lymphomas.
Further research is warranted to validate del(14)(q22) as a diagnostic and prognostic indicator in NHL.